# Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

> **NCT02020577** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 58 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Cetuximab( erbitux®)
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02020577
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-01
- **Final completion:** 2016-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02020577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02020577, "Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02020577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*